Skip to main content

PRA Health Sciences启动了新冠肺炎监测计划

北卡罗莱纳州罗利市, March 24, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences今天宣布了新冠肺炎监测计划的商业可行性,这是一项由移动应用实现的三级计划,允许在雇主、付款人、提供商和卫生系统在大流行期间跟踪可能无症状、有接触史或已确诊新冠肺炎个体的健康状况。
根据个体的新冠肺炎疾病状况,他们可以分为以下三组中的一组:教育计划,针对无症状者,提供生命体征跟踪、预防技术和心理健康支持。隔离计划,针对新冠肺炎接触者,提供注意事项方面的见解,解决恐惧感和孤立感,并联系医护人员。深度监测计划,针对仍然居家的新冠肺炎确诊者,解决症状管理、由医护人员进行的频繁监测以及护理协调的问题。通过将计划的应用下载到个人移动设备上,计划参与者将能够报告与新冠肺炎相关的关键健康指标,如体温、心率和脉搏血氧饱和度。此外,参与者还可以报告呼吸急促、乏力和咳嗽的变化等新冠肺炎的症状。参与者将获得由PRA护士主导的临床呼叫中心工作人员的帮助,后者每天监视通过应用提交的信息。经培训的人员可以解决他们的身体症状和他们可能正在经受的社会及心理影响。“新冠肺炎大流行表明,各种规模的组织都迫切需要能够远程协助个人监测其健康状况的方法。”PRA Health Sciences执行副总裁兼首席科学官Kent Thoelke说, “鉴于新冠肺炎大流行的规模,我们将看到我们的医疗系统及其基础设施会捉襟见肘。通过这项计划,个体能够保持心态平和,他们可以在保持社交隔离的同时,仍然可以舒舒服服地在自己的家中联系医护人员。在这段充满不确定性的时期,与个体进行远程互动的能力对于维护医疗保健基础设施和功能以及患者的安全和业务连续性都至关重要。”此项计划由PRA健康科学公司Care Cares Innovations设计,可在几天内完成部署。该计划建立在云端Health Harmony Digital Health Platform(健康和谐数字卫生平台)上,还可以立即扩展并在指南发生变化时接收更新内容。PRA正在向医疗组织、大型公司部署新冠肺炎监测计划和移动应用,该公司正在与学术机构、政府组织、卫生部门和其他私营企业进行讨论以推广该计划。有关新冠肺炎监测计划的更多信息,请联系Care Innovations,网址:https://www.careinnovations.com/contact/,或致电855-885-CARE。关于PRA HEALTH SCIENCES按营业收入计,PRA(NASDAQ股票代码:PRAH)是世界最大的全球合同研究机构之一,为生物技术和制药行业提供外包临床研发和数据解决方案服务。PRA全球临床研发平台遍及北美、欧洲、亚洲、拉丁美洲、南非、澳大利亚和中东,共75个办事处,全球员工超过17500人。2000年以来,PRA在已参与了世界各地约4000项临床试验。此外,PRA还参与了众多关键性或支持性试验,超过95种产品由此获得了美国食品药品管理局和国际监管机构批准。投资者关系咨询:InvestorRelations@prahs.com媒体咨询:
Laurie Hurst,传播与公共关系总监
HurstLaurie@prahs.com,+1.919.786.8435

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.